CR20220119A - DOSAGE FORMS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION - Google Patents

DOSAGE FORMS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION

Info

Publication number
CR20220119A
CR20220119A CR20220119A CR20220119A CR20220119A CR 20220119 A CR20220119 A CR 20220119A CR 20220119 A CR20220119 A CR 20220119A CR 20220119 A CR20220119 A CR 20220119A CR 20220119 A CR20220119 A CR 20220119A
Authority
CR
Costa Rica
Prior art keywords
dosage forms
bupropion
enantiomerically enriched
pure
pure bupropion
Prior art date
Application number
CR20220119A
Other languages
Spanish (es)
Inventor
Herriot Tabuteau
Original Assignee
Axsome Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74884634&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20220119(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2019/052210 external-priority patent/WO2020061486A2/en
Priority claimed from US16/830,637 external-priority patent/US20200222339A1/en
Priority claimed from US16/907,691 external-priority patent/US11433035B2/en
Application filed by Axsome Therapeutics Inc filed Critical Axsome Therapeutics Inc
Publication of CR20220119A publication Critical patent/CR20220119A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Esta divulgación se refiere a las formas de dosificación que contienen un bupropión enantioméricamente enriquecido o puro, tal como un exceso enantiomérico del (<em>S</em>)-bupropión, del (<em>S</em>)-bupropión enantioméricamente enriquecido o del (<em>S</em>)-bupropión enantioméricamente puro, y a los métodos de uso de estas formas de dosificación. Estas formas de dosificación se pueden administrar a los seres humanos en una cantidad reducida en comparación con la cantidad de bupropión racémico que se administraría en la misma situaciónThis disclosure relates to dosage forms containing enantiomerically enriched or pure bupropion, such as an enantiomeric excess of (<em>S</em>)-bupropion, (<em>S</em>)-bupropion enantiomerically enriched or enantiomerically pure (<em>S</em>)-bupropion, and methods of using these dosage forms. These dosage forms can be administered to humans in a reduced amount compared to the amount of racemic bupropion that would be administered in the same situation.

CR20220119A 2019-09-20 2020-08-18 DOSAGE FORMS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION CR20220119A (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/US2019/052210 WO2020061486A2 (en) 2018-09-20 2019-09-20 Dosage forms and methods for enantiomerically enriched or pure bupropion
US202062971174P 2020-02-06 2020-02-06
US202062978626P 2020-02-19 2020-02-19
US202062992060P 2020-03-19 2020-03-19
US16/830,637 US20200222339A1 (en) 2018-09-20 2020-03-26 Dosage forms and methods for enantiomerically enriched or pure bupropion
US16/907,691 US11433035B2 (en) 2018-09-20 2020-06-22 Dosage forms and methods for enantiomerically enriched or pure bupropion
PCT/US2020/046755 WO2021055124A1 (en) 2019-09-20 2020-08-18 Dosage forms and methods for enantiomerically enriched or pure bupropion

Publications (1)

Publication Number Publication Date
CR20220119A true CR20220119A (en) 2022-06-22

Family

ID=74884634

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220119A CR20220119A (en) 2019-09-20 2020-08-18 DOSAGE FORMS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION

Country Status (15)

Country Link
EP (1) EP4031121A4 (en)
JP (2) JP2022549192A (en)
KR (1) KR20220066930A (en)
CN (1) CN114423417A (en)
AU (3) AU2020349419B2 (en)
BR (1) BR112022005045A2 (en)
CA (2) CA3287347A1 (en)
CO (1) CO2022003126A2 (en)
CR (1) CR20220119A (en)
EC (1) ECSP22030119A (en)
IL (1) IL291514A (en)
MX (1) MX2022003346A (en)
NZ (1) NZ786429A2 (en)
PE (1) PE20221314A1 (en)
WO (1) WO2021055124A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2022003346A (en) * 2019-09-20 2022-04-11 Axsome Therapeutics Inc DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999038502A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (+)-bupropion
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
US20190216800A1 (en) * 2013-11-05 2019-07-18 Axsome Therapeutics, Inc. Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2013014166A (en) * 2013-12-03 2015-06-10 Inst De Investigacion En Quimica Aplic S A De C V Active enantiomers and the salts thereof for treating obesity.
US9732031B2 (en) * 2013-12-20 2017-08-15 Deuterx, Llc Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion
KR20210003091A (en) * 2018-02-23 2021-01-11 액섬 테라퓨틱스, 인크. Dosage forms and methods for enantiomerically enriched or pure bupropion
MX2022003346A (en) * 2019-09-20 2022-04-11 Axsome Therapeutics Inc DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION.

Also Published As

Publication number Publication date
KR20220066930A (en) 2022-05-24
ECSP22030119A (en) 2022-05-31
NZ786429A (en) 2025-08-29
PE20221314A1 (en) 2022-09-07
JP2022549192A (en) 2022-11-24
AU2020349419B2 (en) 2023-11-02
AU2020349419A1 (en) 2022-03-24
NZ786429A2 (en) 2026-01-30
CO2022003126A2 (en) 2022-04-19
MX2022003346A (en) 2022-04-11
IL291514A (en) 2022-05-01
BR112022005045A2 (en) 2022-07-05
AU2026201399A1 (en) 2026-03-19
CA3154718C (en) 2026-02-24
JP2024059812A (en) 2024-05-01
WO2021055124A1 (en) 2021-03-25
CA3287347A1 (en) 2025-11-29
CA3154718A1 (en) 2021-03-25
CN114423417A (en) 2022-04-29
EP4031121A4 (en) 2022-11-30
EP4031121A1 (en) 2022-07-27
AU2024200081A1 (en) 2024-01-25
AU2024200081B2 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
CL2018000897A1 (en) Hair strengthening composition and method to strengthen hair.
CL2018000075A1 (en) Agents, uses and methods for the treatment of synucleinopathy.
MX2020000734A (en) S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same.
CL2020002166A1 (en) Dosage forms and methods for enantiomerically enriched or pure bupropion.
DOP2019000040A (en) SUBSTITUTED PIRROLIZINE COMPOUNDS AND USES OF THE SAME
CL2019001293A1 (en) Agents, uses and methods for the treatment of synucleinopathy.
MX375286B (en) Spiro-lactam NMDA receptor modulators and their uses.
CL2019000248A1 (en) Modulators of the nmda spiro-lactam receptor and use thereof
CO2019011265A2 (en) Modulators of Pcsk9 Expression
CL2018000246A1 (en) Tablet
CL2019000247A1 (en) Modulators of the nmda spiro-lactam receptor and use thereof.
CR20210180A (en) PNPLA3 EXPRESSION MODULATORS
AR105894A1 (en) COMPOSITION FOR TOPICAL APPLICATION THAT INCLUDES ISOSORBID DIMETHYL, A POLYOL, AND A PHENOLIC OR POLYPHENOLIC ANTIOXIDANT
CL2019002218A1 (en) Triple combination formulations and methods to treat or reduce the risk of cardiovascular disease.
CL2015001446A1 (en) Preparation procedure of human albumin with reduced dissolved oxygen level.
MX394318B (en) Pyrazole magl inhibitors
CO2020008769A2 (en) Modulators of the dnm2 expression
ECSP22030119A (en) DOSAGE FORMS AND METHODS FOR ENANTIOMERICALLY ENRICHED OR PURE BUPROPION
MX2019010330A (en) Formulations with improved stability.
MX2018006005A (en) Formulations comprising oxalate salts of teneligliptin and solvates thereof.
UY37261A (en) COMBINED FORMULATION OF THREE ANTIVIRAL COMPOUNDS
ECSP18081486A (en) COMPOSITIONS AND METHODS TO STABILIZE ALFAVIRUS WITH IMPROVED FORMULATIONS
MY198747A (en) Composition for external use
HK40068404A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion
HK40041795A (en) Dosage forms and methods for enantiomerically enriched or pure bupropion